Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSinclair Pharma Regulatory News (SPH)

  • There is currently no data for SPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sinclair secures Euro23 million debt facility

30 Apr 2018 07:00

RNS Number : 4777M
Sinclair Pharma PLC
30 April 2018
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

Sinclair secures €23 million debt facility

 

London, 30 April 2018 Sinclair Pharma plc (AIM:SPH.L) ("Sinclair" or the "Group"), the international aesthetics company, is pleased to announce that it has secured a new €23.0 million debt facility with Hayfin Capital Managament ("Hayfin"). 

 

The facility, a five year term loan which is on cheaper and more flexible terms than the Group's existing bank debt, will be used to repay existing bank debt which amounted to £5.0 million. In addition proceeds will also be used to fund growth (particularly in the Group's direct operations in the US and South Korea); settle deferred consideration liabilities as they come due; and to invest in expanding as well as upgrading and increasing Ellansé® manufacturing capacity and US clinical trial development activities also for Ellansé®.

 

The loan is repayable on 27 April 2023 although it may be repaid at any time, at the Group's option, subject to early prepayment fees. The loan carries an interest rate of EURIBOR plus 9.0%, subject to a EURIBOR floor of 0.75%. No cash interest is payable in the first 18 months of the facility.

 

The facility includes financial covenants relating to the achievement of revenue targets and a requirement to hold a minimum level of cash at all times and is secured by way of a first ranking charge over the Group's assets.

 

Alan Olby, CFO of Sinclair, commented: "I am delighted that we have the support of Hayfin, a well respected, blue chip lender with whom we have maintained a long-term relationship. These additional resources, on more flexible terms, allow us to invest to further accelerate the international footprint and growth of Sinclair."

 

Howard Rowe, Managing Director of Hayfin, commented: "Sinclair has delivered impressive growth over the last two years and we are truly excited by the Group's prospects. We are pleased to once again be a lender to the company and to help facilitate the Sinclair team driving their business forward."

 

Ends

 

 For further information please contact:

 

Sinclair Pharma plc

Tel: +44 (0) 20 7467 6920

Chris Spooner 

 

Alan Olby

 

Andy Crane

 

 

 

Peel Hunt LLP (NOMAD and Joint Broker)

Tel: +44 (0) 20 7418 8900

James Steel

 

Oliver Jackson

 

 

RBC Capital Markets (Joint Broker)

Tel: +44 (0) 20 7653 4000

Marcus Jackson

 

Laura White

 

 

Media enquiries

FTI Consulting

Tel: +44 (0) 203 727 1000

Ben Atwell

 

Brett Pollard

 

Stephanie Cuthbert

 

 

Notes to Editors:

 

About Sinclair Pharma plc - www.sinclairpharma.com 

Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. Sinclair is planning entry to multiple new geographic markets and line extension launches over the next few years. The Group has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors.

 

 

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward‐looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward‐looking statements due to a variety of factors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IODLLFFASRIAFIT
Date   Source Headline
5th Nov 20181:43 pmRNSForm 8.3 - Sinclair Pharma PLC
5th Nov 20187:30 amRNSSuspension - Sinclair Pharma Plc
5th Nov 20187:00 amRNSScheme of Arrangement becomes Effective
2nd Nov 201812:55 pmRNSPUBLIC DEALING DISCLOSURE
2nd Nov 201812:40 pmRNSPUBLIC DEALING DISCLOSURE
2nd Nov 201812:36 pmRNSRule 2.9 Announcement
2nd Nov 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
2nd Nov 20187:44 amRNSForm 8.3 - Sinclair Pharma PLC
1st Nov 20183:45 pmRNSAdditional Listing
1st Nov 20183:08 pmRNSForm 8.3 - Sinclair Pharma plc
1st Nov 201812:43 pmRNSCourt sanction of the scheme of arrangement
31st Oct 20182:25 pmRNSForm 8.3 - Sinclair Pharma plc
30th Oct 20182:29 pmRNSForm 8.3 - Sinclair Pharma plc
29th Oct 20185:30 pmRNSSinclair Pharma
29th Oct 20182:44 pmRNSForm 8.3 - Sinclair Pharma plc
29th Oct 20189:23 amRNSForm 8.3 - Sinclair Pharma Plc
29th Oct 20188:24 amRNSForm 8.3 - Sinclair Pharma PLC
26th Oct 20188:33 amRNSForm 8.3 - Sinclair Pharma PLC
25th Oct 20189:41 amRNSForm 8.3 - Sinclair Pharma PLC
24th Oct 20183:08 pmRNSForm 8.3 - SINCLAIR Pharma PLC
24th Oct 20182:39 pmRNSResults of Court Meeting and General Meeting
23rd Oct 20183:35 pmRNSForm 8.3 - Sinclair Pharma plc
23rd Oct 20182:23 pmRNSHolding(s) in Company
23rd Oct 201812:37 pmGNWMan Group PLC : Form 8.3 - Sinclair Pharma plc
22nd Oct 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
19th Oct 20183:01 pmRNSForm 8.3 - SINCLAIR PHARMA PLC
19th Oct 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
19th Oct 201810:37 amRNSHolding(s) in Company
19th Oct 201810:35 amRNSHolding(s) in Company
18th Oct 20183:20 pmBUSForm 8.3 - Sinclair Pharma PLC
18th Oct 20183:15 pmRNSForm 8.3 - Sinclair Pharma plc
18th Oct 20182:59 pmBUSForm 8.3 - Sinclair Pharma plc
18th Oct 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
18th Oct 201811:58 amRNSForm 8.3 - Sinclair Pharma Plc
18th Oct 201811:42 amGNWMan Group PLC : Form 8.3 - Sinclair Pharma plc
18th Oct 201810:44 amRNSForm 8.3 - Sinclair Pharma Plc
18th Oct 20189:40 amRNSForm 8.3 - [LMR Partners/Sinclair Pharma]
18th Oct 20187:00 amRNSDisclosure under Rule 2.10(c)
17th Oct 20184:49 pmRNSHolding(s) in Company
17th Oct 20184:46 pmRNSHolding(s) in Company
17th Oct 20183:30 pmRNSForm 8.3 - SPH LN
17th Oct 20183:19 pmRNSForm 8.3 - Sinclair Pharma plc
17th Oct 20183:15 pmRNSForm 8.3 - Sinclair Pharma plc
17th Oct 20183:11 pmRNSForm 8.3 - Sinclair Pharma PLC
17th Oct 20183:11 pmBUSForm 8.3 - Sinclair Pharma plc
17th Oct 20182:38 pmRNSForm 8.3 - Sinclair Pharma Plc
17th Oct 201812:30 pmRNSForm 8.3 - Sinclair Pharma plc
17th Oct 201812:29 pmGNWMan Group PLC : Form 8.3 - Sinclair Pharma plc
17th Oct 201812:20 pmRNSForm 8.3 - Sinclair Pharma Plc
17th Oct 20188:06 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.